Morgan Stanley analyst Terence Flynn raised the firm’s price target on Regeneron (REGN) to $761 from $754 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2 report. While Eylea HD made progress during the quarter, Regeneron’s regulatory and pipeline execution will be the key drivers of the stock moving forward, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target raised to $753 from $750 at Bernstein
- Cautious Outlook on Regeneron Despite Strong Performance: Sell Rating Due to Potential Eylea Erosion and Medicare Risks
- Regeneron Pharmaceuticals Reports Strong Q2 2025 Results
- Regeneron Earnings Call: Growth Amid Challenges
- Regeneron’s New Study on MASH: A Potential Game-Changer?